Recent Quotes
My Watchlist
Indicators
Silicon Valley 150
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP: RHHBY )

34.67 +0.15 (+0.43%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 14, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,515,783
Open 34.73
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 34.52
Today's Range 34.52 - 34.88
52wk Range 29.20 - 40.20
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Eli Lilly Drags Alzheimer's Stocks Prothena, Eisai Lower Despite FDA Win
An FDA panel unanimously backed Eli Lilly's Alzheimer's drug, but shares of Lilly and its rivals fell Tuesday. 
Via Investor's Business Daily
Exposures Product Safety
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises
EQNX::TICKER_START (NASDAQ:TLSA),(NYSE:LLY),(OTCQX:RHHBY),(NASDAQ:BIIB),(NASDAQ:TGTX) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures Product Safety

Performance

YTD
-4.62%
-4.62%
1 Month
+10.41%
+10.41%
3 Month
+6.22%
+6.22%
6 Month
-0.17%
-0.17%
1 Year
-10.25%
-10.25%

More News

Read More
Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside
Via Benzinga
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises
From FN Media Group LLC
Via GlobeNewswire
Five-year Data for Genentech’s Evrysdi Show the Majority of Treated Children With a Severe Form of Spinal Muscular Atrophy (SMA) Achieved or Maintained the Ability to Sit, Stand or Walk
From Genentech
Via Business Wire
Italy Probes European Pharma Giants Novartis, Roche Over Eye Drug Competition Allegations
Via Benzinga
2 Cathie Wood Biotech Stocks That Could Be Worth the Risk
Via The Motley Fool
FDA Grants Priority Review to Genentech’s Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation
From Genentech
Via Business Wire
If You'd Invested $100 in Viking Therapeutics Stock 2 Years Ago, Here's How Much You'd Have Today
Via The Motley Fool
Biden Administration Urges Supreme Court Review in Terrorism Funding Lawsuit Against Pharma Companies
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
This Biotech Stock Is Poised For 80% Upside With Breakthrough In Obesity Drug Market, Says JPMorgan
Via Benzinga
FDA Grants Breakthrough Therapy Designation to Genentech’s Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA Mutation
From Genentech
Via Business Wire
Roche To Ride Booming Obesity Treatment Market With Newly-Acquired Drug Candidate
Via Benzinga
Genentech Reports Positive Phase Ib Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People With Obesity
From Genentech
Via Business Wire
Can Ocugen Stock Keep Churning Higher?
Via The Motley Fool
Why Is Penny Stock HOOKIPA Pharma Trading Higher On Wednesday?
Via Benzinga
Exposures Product Safety
2 Small-Cap Growth Stocks With Room To Run
Via The Motley Fool
FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer
From Genentech
Via Business Wire
Genentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS
From Genentech
Via Business Wire
Roche's Lymphoma Drug With Chemo Extends Survival In Pretreated Patients
Via Benzinga
Genentech’s Columvi Meets Primary Endpoint of Overall Survival in People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Study
From Genentech
Via Business Wire
Looking for an Easy Way to Earn Passive Income? This Vanguard ETF Pays a Dividend Yield of Nearly 4.9%.
Via The Motley Fool
Topics ETFs
Why Roche Holdings Stock Popped Today
Via The Motley Fool
Can Recursion Pharmaceuticals Stock Double in 5 Years? Here's What It Would Take.
Via The Motley Fool
Analysts Express Confidence in Alnylam's Hypertension Drug Despite Mixed Trial Data
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.